Iobitridol

Summary

Iobitridol (CHEMBL2107212) is a phase-3 clinical-stage small-molecule radioopaque medium (ATC V08AB11); indicated across 1 condition including acute kidney injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: V08AB11
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 835.2 Da · C20H28I3N3O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107212
Name	Iobitridol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65985
ChEBI	CHEBI:31701
ATC	V08AB11
Molecular formula	C20H28I3N3O9
Molecular weight	835.2
InChIKey	YLPBXIKWXNRACS-UHFFFAOYSA-N

SMILES: CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)NC(=O)C(CO)CO)I)C(=O)N(C)CC(CO)O)I

IUPAC name: 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,4,6-triiodo-1-N,3-N-dimethylbenzene-1,3-dicarboxamide

ChEBI definition: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a 3-hydroxy-2-(hydroxymethyl)propanimido at position 5.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Iobitridol, IOBITRIDOL

Patent coverage: 667 distinct patent families (2,358 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00382317	PHASE4	COMPLETED	A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography
NCT01254552	PHASE4	COMPLETED	Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
NCT01255722	PHASE4	COMPLETED	Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
NCT01908309	EARLY_PHASE1	COMPLETED	Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).